SEC Tracker
Get the app

Dr Reddys Laboratories RDY

Dr Reddys Laboratories reports Q2 revenue of $1.7B

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Revenue for six months ended Sept 30, 2026: $1.7B
  2. Profit for the period: $140M
  3. Total assets as of Sept 30, 2026: $5.9B
  4. Cash and cash equivalents: $139M

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Dr Reddys Laboratories files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX